Evidence map›Paper›PMID 31041423›Full record

ArticlePain reports

Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease.

Janelle E Letzen, Sophie Lanzkron, Kasey Bond, Christopher Patrick Carroll, Jennifer A Haythornthwaite, Sabrina Nance, Claudia M Campbell

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Janelle E LetzenDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sophie LanzkronDivision of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kasey BondDepartment of Hematology and Medical Oncology, New York University Langone Health, New York, NY, USA.
Christopher Patrick CarrollDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jennifer A HaythornthwaiteDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sabrina NanceDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Claudia M CampbellDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USNYU Langone Health · US

Funding

Sleep and Pain in Sickle Cell DiseaseR01HL133327 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CAMPBELL, CLAUDIA MICHELLE, HAYTHORNTHWAITE, JENNIFER A · 2016 to 2019
$3.1M
Neural mechanisms of treatment motivation and adherence in sickle cell diseaseF32HL143941 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI LETZEN, JANELLE E · 2018 to 2019
$129k
NHLBI NIH HHS F32 HL143941NHLBI NIH HHS R01 HL133327
6 · The paper itself

Abstract

introductionHydroxyurea (HU) is a drug that targets the underlying pathophysiology of sickle cell disease (SCD); however, it continues to be an underutilized treatment for adults. Previous research suggests that HU treatment can result in fewer hospital contacts for acute vaso-occlusive pain crises (VOC). Hydroxyurea's impact on non-VOC pain, however, is not well established.

objectivesThis study examined whether HU moderated patterns of static and dynamic pain processing and clinical pain in SCD individuals.

methodsFifty-eight patients with SCD (N taking HU = 17) underwent quantitative sensory testing (QST) and completed twice daily symptom diaries for 12 weeks. Quantitative sensory testing established thermal threshold and tolerance, mechanical thresholds, and thermal and mechanical temporal summation of pain.

resultsGroups did not differ in age, sex, or opioid use. After controlling for morphine use, QST results showed that participants taking HU had higher heat and mechanical pain thresholds (static QST measures) but not thermal and mechanical temporal summation (dynamic QST measures). Participants taking HU also reported lower VOC pain compared with SCD participants not taking HU; however, HU did not moderate non-VOC clinical pain ratings.

conclusionFindings cautiously suggest that HU acts on pain hypersensitivity and VOC pain, rather than inhibiting pain facilitation and non-VOC pain. These differences may reflect HU's influence on peripheral rather than central sensitization. Future research is warranted to replicate these findings in a larger sample and determine whether early HU administration can prevent peripheral sensitization in SCD individuals.

Indexed as

Chronic painHydroxyureaQuantitative sensory testingSickle cell diseaseVOC pain

Identifiers

PMID31041423
PMCPMC6455681
OpenAlexW2923137003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.